PRESS RELEASES
This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.
OKLearn moreWe may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.
Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.
These cookies are strictly necessary to provide you with services available through our website and to use some of its features.
Because these cookies are strictly necessary to deliver the website, you cannot refuse them without impacting how our site functions. You can block or delete them by changing your browser settings and force blocking all cookies on this website.
We also use different external services like Google Webfonts, Google Maps and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.
Google Webfont Settings:
Google Map Settings:
Vimeo and Youtube video embeds:
You can read about our cookies and privacy settings in detail on our Privacy Policy Page.
Privacy Policy
AM-Pharma Raises €116m [$133m] to Conduct Pivotal Phase III Trial of recAP in Acute Kidney Injury
/in Investor, News /by akiibdhAM-Pharma haalt €116 miljoen ($133 miljoen) financiering op voor fase III registratie-studie met kandidaat-medicijn tegen acuut nierfalen (AKI)
/in Investor, News /by akiibdhJAMA publishes Phase II recAP data for sepsis-associated Acute Kidney Injury
/in News, Product /by akiibdhAM-Pharma announces Phase II study results of recAP in sepsis-associated Acute Kidney Injury
/in News, Product /by akiibdhAM-Pharma completes patient recruitment of recombinant human Alkaline Phosphatase
/in News, Product /by akiibdhAM-Pharma publishes safety and pharmacokinetic data from Phase I recAP trial
/in News, Product /by akiibdhAM-Pharma receives FDA fast track designation for recAP in Acute Kidney Injury
/in News, Product /by akiibdhAM-Pharma STOP-AKI Phase II trial nominated for “Most Innovative Clinical Trial Design”
/in News, Product /by akiibdhAM-Pharma and Pfizer Inc. shortlisted for “Best Partnership Alliance” in 2015 Scrip Awards
/in Investor, News /by akiibdhAM-Pharma publishes further preclinical data on recAP to treat Acute Kidney Injury
/in News, Product /by akiibdh